logo/base Created with Sketch.

New Baveno VII Guidelines Further Validate FibroScan® for Management of Patients with Advanced Chronic Liver Disease

In the battle against a worldwide liver disease epidemic, Echosens is proud to announce further validation for the effectiveness of our FibroScan® technologies for the management of patients with advanced chronic liver disease.

The latest Baveno VII guidelines fully validate that vibration-controlled transient elastography (LSM by VCTE™), controlled attenuation parameter (CAP™) and spleen stiffness measurement (SSM by VCTE™) provide a powerful level of support for its use among specialists. These guidelines renew consensus in personalized care for patients with compensated advanced chronic liver disease (cACLD), clinically significant portal hypertension (CSPH) and esophageal varices.

Baveno VII guidelines have a global impact, adding to the growing list of endorsements for our technology by many societies across the world.

Important Validation for Non-invasive FibroScan® 

FibroScan® is a quick and painless exam that can be performed in less than 10 minutes to provide immediate results at point-of-care. Validation of LSM by VCTE™ serves as the cornerstone of non-invasive tests to improve risk stratification and enhance clinical decision making.

The Baveno VII guidelines recommend LSM by VCTE™ for monitoring cACLD patients, with clear cut-offs provided to identify substantially reduced risk of decompensation and liver-related death. The guidelines for monitoring cACLD patients state the test can be repeated every 12 months. A clinically significant decrease in LSM, which is associated with substantially reduced risk of decompensation and liver-related death, can be defined as a decrease in LSM of ≥20% associated with LSM<20 kPa or any decrease to a LSM<10 kPa.

Other Scientific Community Endorsements

The Baveno VII Consensus workshop was endorsed and supported with unrestricted grants by international scientific societies, including European Association for the Study of the Liver (EASL), and national scientific societies, as well as the American Association for the Study of Liver Disease (AASLD), Spanish Association for the Study of the Liver (AEEH), French Association for the Study of the Liver (AFEF), Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) Italian Association for the Study of the Liver (AISF), Spanish network of biomedical investigation in liver and digestive diseases (CIBERehd), Austrian Society for Gastroenterology and Hepatology (ÖGGH), Swiss Association for the Study of the Liver (SASL) and Italian Society of Gastroenterology (SIGE).

The Baveno VII guidelines help strengthen our mission to battle liver disease around the world. We will continue to innovate and improve the management of silent, underdiagnosed chronic liver disease, including nonalcoholic fatty liver disease (NAFLD) and its more severe form nonalcoholic steatohepatitis (NASH).

chevron Access the Baveno VII guidelines related to FibroScan®